Characterisation of Patient Profile and Contemporary Treatment of Pre-dialytic Chronic Kidney Disease (CKD) in Patients Receiving a Restricted Protein Diet Supplemented With Ketosteril® - a Drug Utilisation Study (DUS)

Fresenius Kabi1 site in 1 country164 target enrollmentFebruary 2016

ConditionsChronic Kidney Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Chronic Kidney Disease
Sponsor: Fresenius Kabi
Enrollment: 164
Locations: 1
Primary Endpoint: Patient compliance to Ketosteril (number of tablets taken; patient-reported)
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to characterise the patient and disease profile under the influence of a protein-restricted diet supplemented with keto acids/amino acids (KA/AA), focusing on the progression of chronic renal insufficiency, calcium and phosphorus metabolism, nutritional status, patient compliance to diet and Ketosteril intake as well as the persistent dietary education to ensure compliance in a large group of pre-dialysis patients.

Registry

clinicaltrials.gov

Start Date

February 2016

End Date

October 9, 2018

Last Updated

7 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Fresenius Kabi

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•written informed consent
•non-dialyzed patients with CKD
•indication for Ketosteril according to Summary of Product Characteristics (SmPC), including a glomerular filtration rate (GFR) \< 25 mL/min
•accepted supplemented protein-restricted diet and newly starting with Ketosteril (treatment naïve, i.e., never treated with Ketosteril before)
•adult patients ≥ 18 years

Exclusion Criteria

•active cancer diseases
•pregnancy or breast feeding
•hypersensitivity to active substances or to any of the excipients in Ketosteril
•hypercalcaemia
•major disorder of amino acid metabolism, e.g., hereditary diseases
•participation in any clinical trial with an investigational drug within 30 days prior to start of study or during the study
•illiteracy or incapability to read or write

Outcomes

Primary Outcomes

Patient compliance to Ketosteril (number of tablets taken; patient-reported)

Time Frame: Daily, for a total of 12 months

This is an observational study aiming to characterise the patient profile and contemporary treatment of pre-dialytic chronic kidney disease (CKD) in patients receiving a restricted protein diet supplemented with Ketosteril® . There is no distinction between primary and secondary outcome measures in the observational plan, and only routine procedures are documented.

Secondary Outcomes

Decline in eGFR(At 3, 6, 9 and 12 months after enrolment)
Worsening of CKD stage(At 3, 6, 9 and 12 months after enrolment)
Presence of a 50% reduction in eGFR(At 3, 6, 9 and 12 months after enrolment)
Serum bicarbonate(At baseline and 3, 6 and 12 months after enrolment)
Serum low-density lipoprotein (LDL)(At baseline and 3, 6, 9 and 12 months after enrolment)
Serum high-density lipoprotein (HDL)(At baseline and 3, 6, 9 and 12 months after enrolment)
Serum total protein(At baseline and 3, 6, 9 and 12 months after enrolment)
Serum albumin(At baseline and 3, 6, 9 and 12 months after enrolment)
Body mass index(At baseline and 3, 6, 9 and 12 months after enrolment)
Subjective Global Assessment(At baseline and 3, 6, 9 and 12 months after enrolment)
Serum haemoglobin(At baseline and 3, 6 and 12 months after enrolment)
CKD stage (according to KDIGO guideline)(At baseline and 3, 6, 9 and 12 months after enrolment)
Fasting plasma glucose(At baseline and 3, 6, 9 and 12 months after enrolment)
Start of dialysis(At 3, 6, 9 and 12 months after enrolment)
Presence of comorbidities(At baseline)
Serum creatinine(At baseline and 3, 6, 9 and 12 months after enrolment)
Serum calcium(At baseline and 3, 6, 9 and 12 months after enrolment)
Serum parathyroid hormone(At baseline and 3, 6, 9 and 12 months after enrolment)
Weight(At baseline and 3, 6, 9 and 12 months after enrolment)
Serum prealbumin(At baseline and 3, 6, 9 and 12 months after enrolment)
Serum urea(At baseline and 3, 6, 9 and 12 months after enrolment)
Fasting blood glucose(At baseline and 3, 6, 9 and 12 months after enrolment)
HbA1c(At baseline and 3, 6, 9 and 12 months after enrolment)
Creatinine clearance(At baseline and 3, 6, 9 and 12 months after enrolment)
Glomerular filtration rate (GFR)(At baseline and 3, 6, 9 and 12 months after enrolment)
Estimated glomerular filtration rate (eGFR)(At baseline and 3, 6, 9 and 12 months after enrolment)
Serum triglyceride(At baseline and 3, 6, 9 and 12 months after enrolment)
Skinfold thickness(At baseline and 3, 6, 9 and 12 months after enrolment)
Serum phosphate(At baseline and 3, 6, 9 and 12 months after enrolment)
Serum potassium(At baseline and 3, 6 and 12 months after enrolment)
Patient compliance to diet (protein and energy intake, based on a routine 3-day food diary)(Monthly starting 1 month after enrolment, for a total of 12 months)
24h urinary protein(At baseline and 3, 6, 9 and 12 months after enrolment)
Serum cholesterol(At baseline and 3, 6, 9 and 12 months after enrolment)
Urinary microalbumin(At baseline and 3, 6, 9 and 12 months after enrolment)
Acceptance of diet as documented in the patient diary(Daily for up to 12 months)
Heart rate(At baseline and 3, 6, 9 and at 12 months after enrolment)
Reported nausea and vomiting(At baseline and 3, 6 and 12 months after enrolment)
Change of food intake as documented in the patient diary(Daily for up to 12 months)
Presence of concomitant disease(At 3, 6, 9 and 12 months after enrolment)
Administration of concomitant medication(At 3, 6, 9 and 12 months after enrolment)
Discontinuation of diet and Ketosteril with the reasons for discontinuation as reported by the investigator(Monthly starting at 1 month after enrolment for up to 12 months)
Appetite change as documented in the patient diary(Daily for up to 12 months)
Adverse events including adverse drug reactions and serious adverse events(At 3, 6, 9 and 12 months after enrolment)
Body temperature(At baseline and 3, 6, 9 and at 12 months after enrolment)
Blood pressure(At baseline and 3, 6, 9 and at 12 months after enrolment)